摘要
目的比较超声消融治疗局限型和弥漫型子宫腺肌病的安全性及有效性。方法选择2010年11月至2011年10月四川省遂宁市中心医院收治的111例接受超声消融治疗的子宫腺肌病患者,对其中完成并具有完整随访资料的103例子宫腺肌病患者进行回顾性分析(1年期随访),其中局限型67例,弥漫型36例。评价术后痛经、月经量改善程度,观察不良反应发生情况。结果两组患者在接受超声消融治疗后,痛经及月经量过多均显著改善,术后12个月痛经症状完全缓解率局限型为62.1%,弥漫型为43.8%;月经量过多症状完全缓解率局限型为72.1%,弥漫型为56.0%。局限型组与弥漫型组比较,除弥漫型组月经量评分在12个月随访时显著高于局限型组外(P=0.031),其他各指标两组间差异均无统计学意义。结论超声消融治疗能安全有效缓解子宫腺肌病患者的症状,局限型与弥漫型子宫腺肌病均适合超声消融治疗。
Objective To evaluate the efficacy and safety of high intensity focused ultrasound( HIFU) ablation for focal adenomyosis and diffuse adenomyosis. Methods From November 2010 to October 2011,one hundred and eleven patients with adenomyosis were treated with HIFU in Suining central hospital. One hundred and three patients completed 12-month follow up. Among them,67 with focal adenomyosis,while 36 with diffuse adenomyosis. The menorrhagia severity score,the dysmenorrhea severity pain score,were evaluated. Results The menorrhagia severity score,the dysmenorrhea severity pain score were significantly decreased in patients with focal adenomyosis or with diffuse adenomyosis. The complete remission rate of dysmenorrhea of focal adenomyosis in 12 months after HIFU was 62. 1%,diffuse adenomyosis was 43. 8%; The complete remission rate of menorrhagia of focal adenomyosis in 12 months after HIFU was 72. 1%,diffuse adenomyosis was 56. 0%. The menorrhagia severity score in 12 months after HIFU was significantly higher in patients with diffuse adenomyosis than that in patients with focal adenomyosis( P = 0. 031). No any other significantly difference was observed between the two groups( P > 0. 05). Conclusion HIFU appears to be a safe and effective technique to ablate both focal and diffuse adenomyotic lesions to alleviate the symptoms of menorrhagia or dysmenorrhea.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2014年第3期217-219,共3页
Chinese Journal of Practical Gynecology and Obstetrics
基金
国家自然科学基金重点项目(No:30830040)
国家十一五科技支撑计划(No:2006BAI03A02)
重庆市科委攻关项目(渝科发计字No:[2007]11CSTC
2007AA502)
